Evotec preliminary nine-month revenue near €465M

Evotec said preliminary nine-month 2026 figures exceeded market expectations and reaffirmed its full-year revenue and adjusted EBITDA guidance.

Rhea-AI Filing Summary

Evotec SE (EVO) announced preliminary, unaudited Group revenue of approximately €465.0 million and adjusted Group EBITDA of approximately -€42.8 million for the first nine months of 2026. The company said these figures were above current market expectations, with the variance driven largely by the phasing of consensus estimates.

Evotec reaffirmed full-year 2026 guidance: Group revenue of approximately €570 million to €610 million (€595 million to €635 million at CER) and adjusted Group EBITDA of approximately -€70 million to -€105 million (-€60 million to -€90 million at CER). Full third-quarter and nine-month results are scheduled for publication on November 5, 2026.

Key Figures

Group revenue: Approximately €465.0 million Adjusted Group EBITDA: Approximately -€42.8 million Group revenue guidance: Approximately €570 million to €610 million +3 more

6 metrics

Group revenue Approximately €465.0 million Preliminary first nine months of 2026

Adjusted Group EBITDA Approximately -€42.8 million Preliminary first nine months of 2026

Group revenue guidance Approximately €570 million to €610 million Full-year 2026

Group revenue guidance at CER €595 million to €635 million Full-year 2026

Adjusted Group EBITDA guidance Approximately -€70 million to -€105 million Full-year 2026

Adjusted Group EBITDA guidance at CER -€60 million to -€90 million Full-year 2026

Key Terms

adjusted Group EBITDA, CER, consensus estimates

3 terms

adjusted Group EBITDA financial

"adjusted Group EBITDA of approximately -€42.8 million"

CER financial

"€595 to €635 million at CER"

consensus estimates financial

"the phasing of consensus estimates"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were EVO's preliminary nine-month 2026 results?

Evotec reported preliminary, unaudited first-nine-month Group revenue of approximately €465.0 million and adjusted Group EBITDA of approximately -€42.8 million. Evotec said these figures were above current market expectations, with the variance driven largely by the phasing of consensus estimates.

When will Evotec publish its full third-quarter and nine-month 2026 results?

Full financial results for the third quarter and first nine months of 2026 are scheduled for publication on November 5, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/14/2026 - 06:04 AM EDT Accepted by SEC EDGAR 10/14/2026 - 06:02 AM EDT Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of October, 2026

COMMISSION FILE NUMBER 001-34041

Evotec SE
(Translation of registrant’s name into English)

Essener Bogen 7

22419 Hamburg

Germany

Tel: +49 40 560810
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F: Form 20-F xForm 40-F ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

On October 13, 2026, Evotec SE (the “Company”) issued an Ad hoc announcement. A copy of the Ad hoc announcement is attached as Exhibit 99.1 hereto.

EXHIBIT INDEX

Exhibit	Description of Exhibit
99.1	Evotec announces preliminary nine-months 2026 results above market expectations, reaffirming full-year 2026 guidance

SIGNATURE

Pursuant to the requirements, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Evotec SE
	By:	/s/ Claire Hinshelwood
		Name: Claire Hinshelwood
		Title: Chief Financial Officer

Date: October 14, 2026

Exhibit 99.1 

Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014

Ad hoc: Evotec announces preliminary nine-months 2026 results above market expectations, reaffirming full-year 2026 guidance

Hamburg, Germany – Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT) today announced preliminary unaudited financial results for first nine months of 2026. Full financial results for the third quarter and the first nine months of 2026 will be published on November 5, 2026, as scheduled.

Based on preliminary figures, Evotec expects Group revenues for the first nine months of 2026 of approximately €465.0 million and adjusted Group EBITDA of approximately -€42.8 million. These figures are above current market expectations, with the variance driven largely by the phasing of consensus estimates.

Evotec reaffirms its full-year 2026 guidance, which projects Group revenues of approximately €570 to €610 million (€595 to €635 million at CER) and adjusted Group EBITDA of approximately -€70 to -€105 million (-€60 to -€90 million at CER).

– End of the ad hoc release –

Contact: Dr. Sarah Fakih, EVP Head of Global Communications and Investor Relations, Evotec SE, Manfred Eigen Campus, Essener Bogen 7, 22419 Hamburg, Germany, Phone: +49 (0) 151 7068 8784 (m), sarah.fakih@evotec.com

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 EXHIBIT 99.1 3.8 KB